LeapZipBlog: Johnson Paul's blog: Cervical Cancer Diagnostic Test Market Size, Share, Growth, Trends, Analysis and Forecast 2018 To 2026 | Credence Research

Cervical Cancer Diagnostic Test Market Size, Share, Growth, Trends, Analysis and Forecast 2018 To 2026 | Credence Research

June 19, 2019 by Johnson Paul  

Credence Research 1

The latest market report published by Credence Research, Inc. “Cervical Cancer Diagnostic Test Market  By Diagnostic Test Type (PAP Tests, HPV Tests, Biopsy, Colposcopy, Cystoscopy) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026” the cervical cancer diagnostic test market was valued at US$ 8,779.2 Mn in 2017 and expected to reach US$ xx Mn by 2026 at a CAGR of 8.6 % during the forecast period from 2018 to 2026.

Browse the full report Cervical Cancer Diagnostic Test Market Growth, Future Prospects, and Competitive Analysis, 2018 - 2026 at https://www.credenceresearch.com/report/cervical-cancer-diagnostic-test-market

Market Insights

An infection or abnormal cell growth on the surface of the cervix leads to cervical cancer, develop uncontrollably, and frame a tumor. Cervical cancer diagnostics test is the primary examination of the cancer patients, done through Pap (Papanicolaou) smear test and HPV (Human papillomavirus) testing, in the following stage colposcopy and biopsy performed additionally to affirm further testing procedure. After the analysis performed effectively the patients at that point experiences imaging tests to begin the review of growth. Pap tests deliver real-time analysis of current cell growth, and specify whether abnormal cell growth or tumor expected to become more cancerous in the future. Superior screening with HPV testing and Pap smear testing has significantly condensed mortality rate from cervical cancer globally; such testing can prevent cancers through early detection of abnormal cell growth and improved health care management.

In 2014, as per the American Cancer Society, there were in excess of 12,000 new instances of cervical malignancy in the U.S. furthermore; more than 4,000 deaths registered from cervical cancer. High prevalence of the disease worldwide, majorly from developing nations i.e. more than 80% is driving the market growth of cervical cancer diagnostics market. According to the World Health Organization, cervical cancer is mainly responsible for more than 300,000 deaths annually worldwide.

Development of cervical cancer diagnostic test market driven by growing female population worldwide and rising predominance rate of cervical disease, high occurrence rate of HPV (human papilloma virus) contaminations, rising number of awareness programs for cervical malignancy, and government funding and initiatives for early cure. Advanced products and innovations, and critical development in the HPV testing provides better opportunities in the worldwide market. In any case, changes in the regulations for cervical disease screening, and utilization of HPV antibodies are the key factors that are constraining development of this market. Additionally, unverifiable reimbursement scenario is the key market challenge in this market. The other prominent growth factors include increasing diagnostic procedures worldwide with higher efficacy, increasing healthcare expenditure, better reimbursement coverage, and utilization of advance diagnostic procedures in developing nations offers potential advantage to the further growth of the market.

In any case, lack of early diagnosis and treatment, high financial investment and expensive medications, strict administrative rules, and reimbursement approach issues are the key components limiting the market growth during the forecast period. In addition, the worldwide monetary conditions in the healthcare sector in developing economies make a noteworthy open door for the extension of the market.

Key Market Movements:

  • Globally, the cervical cancer diagnostic test market remains to exhibit a profitable growth with a CAGR of 8.6% for the period from 2018 to 2026
  • Based on the diagnostic test type, the Pap test segment shows lucrative growth with increasing applications in the diagnostic procedures due to its ease of availability and accurate results. The development of the worldwide cervical cancer diagnostic test market mainly attributed to high pervasiveness of the cancer disorders, higher adoption of Pap and HPV testing in the end user segment and higher technology assessment in the new products with increased efficacy along with higher output for early detection and better healthcare management.
  • North America to contribute maximum revenue share in the overall growth of the cervical cancer diagnostic test market attributed to rising prevalence of cervical cancer, increasing ECC procedures & colposcopy tests, rising female & obese population, unsafe sex, smoking, and huge number of patients suffering from HPV infection. Increasing awareness and programs held by top cancer care institutes, maximum reimbursement coverage, higher patient safety and the presence of top manufacturers & sophisticated healthcare infrastructure in the U.S. and Canada is contributing maximum revenue share in the overall cervical cancer diagnostic test market.
  • Eastern Europe, Latin America, and Asia Pacific to shows promising opportunities and shows growing CAGR during the forecast period owing to rising awareness among the individuals about the cervical cancer diagnostic test and its utilization. Surging population & a number of advanced healthcare settings, availability of branded test kits and instruments, and increasing healthcare spending in Russia, Brazil, India, China, and Japan may contribute the growth of the market during the forecast period.
  • Major players in this vertical are Hologic Corporation, Becton, Dickinson and Company, Qiagen N.V., Siemens Healthcare, Guided Therapeutics Inc., Ascon Medical Instruments Pvt Ltd, Hoffmann-La Roche., Cooper Surgical Inc., Cardinal Health, Inc., Beckman Coulter Inc. and others.

Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/59296

Table of Content

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Cervical Cancer Diagnostic Test Market Portraiture
2.2. Global Cervical Cancer Diagnostic Test Market, By Diagnostic Test Type, 2017 (US$ Mn)
2.3. Global Cervical Cancer Diagnostic Test Market, by Geography, 2017 Vs 2026 (Value %)

Chapter 3. Global Cervical Cancer Diagnostic Test Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. Cervical Cancer Diagnostic Test: Future Trends
3.3. Current Scenario: Strategies Used for Drug Delivery Across BBB Drivers
3.4. Challenges
3.5. Opportunities
3.6. Attractive Investment Proposition, by Geography, 2017
3.7. Major Agreements, Partnerships and Collaborations
3.8. Competitive Landscape
3.8.1. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Cervical Cancer Diagnostic Test Market, by Diagnostic Test Type, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. PAP Tests 
4.3. HPV Tests
4.4. Biopsy
4.4.1. Cone biopsy
4.4.2. Endocervical Curettage
4.4.3. Punch biopsy & Others
4.5. Colposcopy
4.6. Cystoscopy

Chapter 5. Global Cervical Cancer Diagnostic Test Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. North America Cervical Cancer Diagnostic Test Market Analysis, 2016 – 2026 
5.2.1. North America Cervical Cancer Diagnostic Test Market, By Diagnostic Test Type, 2016 – 2026 (US$ Mn)
5.2.2. North America Cervical Cancer Diagnostic Test Market, by Country, 2016 – 2026 (US$ Mn)
5.2.2.1. U.S.
5.2.2.2. Canada
5.3. Europe Cervical Cancer Diagnostic Test Market Analysis, 2016 – 2026 
5.3.1. Europe Cervical Cancer Diagnostic Test Market, By Diagnostic Test Type, 2016 – 2026 (US$ Mn)
5.3.2. Europe Cervical Cancer Diagnostic Test Market, by Country, 2016 – 2026 (US$ Mn)
5.3.2.1. U.K.
5.3.2.2. Germany
5.3.2.3. Rest of Europe
5.4. Asia Pacific Cervical Cancer Diagnostic Test Market Analysis, 2016 – 2026 
5.4.1. Asia Pacific Cervical Cancer Diagnostic Test Market, By Diagnostic Test Type, 2016 – 2026 (US$ Mn)
5.4.2. Asia Pacific Cervical Cancer Diagnostic Test Market, by Country, 2016 – 2026 (US$ Mn)
5.4.2.1. Japan
5.4.2.2. China
5.4.2.3. Rest of APAC
5.5. Latin America Cervical Cancer Diagnostic Test Market Analysis, 2016 – 2026 
5.5.1. Latin America Cervical Cancer Diagnostic Test Market, By Diagnostic Test Type, 2016 – 2026 (US$ Mn)
5.5.2. Latin America Cervical Cancer Diagnostic Test Market, by Country, 2016 – 2026 (US$ Mn)
5.5.2.1. Brazil
5.5.2.2. Mexico
5.5.2.3. Rest of Latin America
5.6. Middle East & Africa (MEA) Cervical Cancer Diagnostic Test Market Analysis, 2016 – 2026 
5.6.1. MEA Cervical Cancer Diagnostic Test Market, by Diagnostic Test Type, 2016 – 2026 (US$ Mn)
5.6.2. MEA Cervical Cancer Diagnostic Test Market, by Region, 2016 – 2026 (US$ Mn)
5.6.2.1. GCC
5.6.2.2. Rest of MEA

Chapter 6. Company Profiles
6.1. Hologic Corporation
6.1.1. Business Description
6.1.2. Financial Information (Subject to data availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Becton, Dickinson and Company
6.3. Qiagen N.V.
6.4. Siemens Healthcare
6.5. Guided Therapeutics, Inc.
6.6. Ascon Medical Instruments Pvt Ltd
6.7. Hoffmann-La Roche
6.8. Cooper Surgical Inc.
6.9. Cardinal Health, Inc.
6.10. Beckman Coulter Inc.

Do Enquiry before Buying for research report: https://www.credenceresearch.com/inquiry-before-buying/59296

Blog: https://medium.com/@kumarganesh028/cervical-cancer-diagnostic-test-market-size-share-growth-trends-analysis-and-forecast-2018-to-f12b7c74e5ac

About Us

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.

Media Contact

Name: Chris Smith

Address: 105 N 1st ST #429,

SAN JOSE, CA 95103 US

Toll-Free (US/CANADA) Ph.: +1-800-361-8290

E-mail: sales@credenceresearch.com

Website: http://www.credenceresearch.com